Paige vs Lunit
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Paige
Cancer pathology AI behind the FDA-authorised Paige Prostate, now part...
Visit
|
Lunit
KOSDAQ-listed Korean AI for breast and chest cancer screening
Visit
|
|
|---|---|---|
| RECATOOLS Score | 8.2 / 10 | 6.7 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Custom | Enterprise |
| Free tier | — | — |
| Paid from | Quoted per deployment; 30-day trial of the diagnostic suites on request | No public $ price — quoted per institution via Lunit sales and imaging partners |
| Has API | ✓ | ✗ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✗ |
| Users | In clinical use at hospitals and labs worldwide; training data spans 800+ labs across 45 countries | — |
| Founded | 2017 | 2015 |
| Maker | Tempus AI | — |
| Verdict | Paige has the strongest regulatory record in AI pathology: a 2021 FDA De Novo authorisation for Paige Prostate, Breakthrough designations, and CE and UKCA marks across its suites. The evidence deserves careful reading, t... |
Lunit is one of the few medical-AI vendors with substantial revenue behind it: KRW 45.8 billion in the first half of 2026, up 23%, almost all earned abroad, though it is still loss-making and completed a KRW 211.5 billio... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.